VALIDATION OF THE APIXABAN COST-EFFECTIVENESS MODEL IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION

被引：0
|
作者：
Kachroo, S. [1 ]
Phatak, H. [1 ]
Dorian, P. [2 ]
Kongnakorn, T. [3 ]
Lanitis, T. [4 ]
Kuznik, A. [5 ]
Mardekian, J. [6 ]
Liu, X. [7 ,8 ]
Lawrence, J. [1 ]
Lip, G. Y. [9 ]
机构：
[1] Bristol Myers Squibb Co, Princeton, NJ USA
[2] Univ Toronto, Toronto, ON, Canada
[3] Evidera, Bangkok, Thailand
[4] Evidera, London, England
[5] Celgene Corp, Summit, NJ USA
[6] Pfizer, New York, NY USA
[7] Pfizer Inc, New York, NY USA
[8] Univ Tennessee, Coll Pharm, Knoxville, TN USA
[9] Univ Birmingham, Birmingham, W Midlands, England
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 03期
关键词：
D O I：
10.1016/j.jval.2014.03.661
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCV67
引用
收藏
页码：A113 / A113
页数：1
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS OF RIVAROXABAN IN THE PREVENTION OF STROKE IN NON-VALVULAR ATRIAL FIBRILLATION PATIENTS IN ITALY
    Capri, S.
    Veneziano, M.
    Ricciardi, W. G.
    D'Ausilio, A.
    Pedone, M. P.
    Bianchi, C.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A525 - A526
  • [22] Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation: A Cost-Effectiveness Analysis
    Rognoni, Carla
    Marchetti, Monia
    Quaglini, Silvana
    Liberato, Nicola Lucio
    [J]. CLINICAL DRUG INVESTIGATION, 2014, 34 (01) : 9 - 17
  • [23] Apixaban, Dabigatran, and Rivaroxaban Versus Warfarin for Stroke Prevention in Non-Valvular Atrial Fibrillation: A Cost-Effectiveness Analysis
    Carla Rognoni
    Monia Marchetti
    Silvana Quaglini
    Nicola Lucio Liberato
    [J]. Clinical Drug Investigation, 2014, 34 : 9 - 17
  • [24] APPLICATION OF NEW FRENCH GUIDELINES FOR ECONOMIC EVALUATIONS: A COST-EFFECTIVENESS ANALYSIS OF APIXABAN IN PATIENTS WITH NON-VALVULAR ATRIAL FIBRILLATION IN FRANCE
    Durand-Zaleski, I
    Cotte, F. E.
    Lanitis, T.
    Godard, C.
    Kachaner, I
    Kongnakorn, T.
    Gaudin, A. F.
    [J]. VALUE IN HEALTH, 2013, 16 (07) : A523 - A523
  • [25] Cost-Effectiveness of Apixaban versus Warfarin in Chinese Patients with Non-Valvular Atrial Fibrillation: A Real-Life and Modelling Analyses
    Li, Xue
    Tse, Vicki C.
    Lau, Wallis C. Y.
    Cheung, Bernard M. Y.
    Lip, Gregory Y. H.
    Wong, Ian C. K.
    Chan, Esther W.
    [J]. PLOS ONE, 2016, 11 (06):
  • [26] Apixaban Levels in Octogenarian Patients with Non-valvular Atrial Fibrillation
    Nissan, Ran
    Spectre, Galia
    Hershkovitz, Avital
    Green, Hefziba
    Shimony, Shai
    Cooper, Lisa
    Nakav, Sigal
    Shochat, Tzippy
    Grossman, Alon
    Fuchs, Shmuel
    [J]. DRUGS & AGING, 2019, 36 (02) : 165 - 177
  • [27] Apixaban Levels in Octogenarian Patients with Non-valvular Atrial Fibrillation
    Ran Nissan
    Galia Spectre
    Avital Hershkovitz
    Hefziba Green
    Shai Shimony
    Lisa Cooper
    Sigal Nakav
    Tzippy Shochat
    Alon Grossman
    Shmuel Fuchs
    [J]. Drugs & Aging, 2019, 36 : 165 - 177
  • [28] Comparative effectiveness and safety of apixaban, dabigatran, and rivaroxaban in patients with non-valvular atrial fibrillation
    Andersson, Niklas W.
    Svanstrom, Henrik
    Lund, Marie
    Pasternak, Bjorn
    Melbye, Mads
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2018, 268 : 113 - 119
  • [29] Cost analysis: apixaban versus other anticoagulation in patients with non-valvular atrial fibrillation
    Kunde, Katharina
    [J]. GESUNDHEITSOEKONOMIE UND QUALITAETSMANAGEMENT, 2022, 27 (06): : 282 - 283
  • [30] Cost-effectiveness of Dabigatran for Stroke Prevention in Non-valvular Atrial Fibrillation in Spain
    Gonzalez-Juanatey, Jose R.
    Alvarez-Sabin, Jose
    Lobos, Jose M.
    Martinez-Rubio, Antoni
    Reverter, Joan C.
    Oyagueez, Itziar
    Gonzalez-Rojas, Nuria
    Becerra, Virginia
    [J]. REVISTA ESPANOLA DE CARDIOLOGIA, 2012, 65 (10): : 901 - 910
12345